Cone-rod dystrophy vs rod-cone dystrophy – differentiating features Leber congenital amaurosis – clinical features, genetics, management (voretigene neparvovec). Role of genetic counseling in inherited retinal disorders. Fundus autofluorescence in IRDs Bull's eye maculopathy – differential diagnosis Autofluorescence vs FFA in RP Answers to these questions
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Finding Sources
Searching PubMed
voretigene neparvovec RPE65 Leber congenital amaurosis gene therapy
Searching the Web
cone-rod vs rod-cone dystrophy differentiating features ERG genetics clinical
Reading File
Reading File
Searching the Web
fundus autofluorescence vs FFA fluorescein angiography retinitis pigmentosa inherited retinal dystrophy comparison
Reading File
Reading File
Searching the Web
Leber congenital amaurosis genetics genes RPE65 CEP290 CRB1 management voretigene 2024 2025
Reading File
Reading File
Searching the Web
genetic counseling inherited retinal dystrophy role recurrence risk family members molecular testing 2024
Reading File
Reading File
Reading File
Reading File
Inherited Retinal Dystrophies (IRDs) - Comprehensive Answers
1. Cone-Rod Dystrophy vs Rod-Cone Dystrophy - Differentiating Features
These two entities lie at opposite ends of the photoreceptor degeneration spectrum. The fundamental distinction is which photoreceptor degenerates first and most severely, and this drives every clinical, electrophysiological and genetic difference.
Core Concept
| Feature | Rod-Cone Dystrophy (RP prototype) | Cone-Rod Dystrophy (CRD) |
|---|---|---|
| Primary cell death | Rods first, cones later | Cones first (or predominant), rods later |
| First symptom | Nyctalopia (night blindness) | Reduced central VA + photophobia |
| Visual field loss | Peripheral (ring scotoma → tunnel vision) | Central/paracentral scotoma first |
| Colour vision | Preserved early, lost late | Affected early - severe deutero-tritan defect |
| Photophobia | Mild or absent early | Prominent early feature |
| Day/night | Night vision fails first | Day vision (hemeralopia) fails first |
| Nystagmus | Uncommon | Present in early-onset severe forms |
| Prognosis | Progressive peripheral loss; central preserved longer | Central vision lost early; legal blindness by mid-adulthood |
ERG - The Key Differentiating Tool
- Rod-cone dystrophy (RP): Scotopic (rod) responses are disproportionately reduced compared to photopic. Early RP shows markedly abnormal scotopic ERG with relatively preserved photopic. Combined rod-cone ERG shows large amplitude reduction.
- Cone-rod dystrophy: Photopic responses (single-flash cone + 30 Hz flicker) are selectively reduced or extinguished early. Scotopic rod responses are preserved or mildly reduced initially, only becoming severely abnormal in late disease. Implicit time delays in the 30 Hz flicker ERG are an early sign.
(Kanski's Clinical Ophthalmology 10th ed., p. 637-651; Miyake & Shinoda in Retina 5th ed.)
Fundus
- RP (rod-cone): Classic triad - bone-spicule pigmentation (perivascular, mid-peripheral), arteriolar attenuation, waxy disc pallor. Peripheral changes predominate.
- CRD: Early changes are macular - non-specific RPE granularity, golden sheen (X-linked), bull's-eye maculopathy, progressive RPE atrophy. Peripheral changes develop later.
Genetics
- RP genes (rod-cone): Rhodopsin (RHO, AD), RPGR (X-linked, 90% of X-linked cases), PRPF31, USH2A, EYS, CRB1, >100 gene loci total.
- CRD genes: ABCA4, GUCY2D, CRX, PRPH2, RPGR, CACNA1F, CNGB3 - at least 30 genes; majority AR, some AD and X-linked.
- Notably, ABCA4 mutations cause Stargardt (macular) → CRD spectrum; RPGR mutations can cause both RP and CRD depending on mutation type.
Dark Adaptation Curve
- RP: Rod branch is markedly elevated (raised threshold); rod-cone break is delayed or absent.
- CRD: Cone branch is abnormal; rod branch initially normal or near-normal in early disease.
2. Leber Congenital Amaurosis (LCA)
Definition and Epidemiology
LCA is the most severe inherited retinal dystrophy presenting at birth or in early infancy. It accounts for ~5% of all RP and is the most common cause of inherited childhood blindness. Prevalence: ~1 in 80,000. (Kanski 10th ed., p. 636)
Clinical Features
The cardinal tetrad:
- Blindness at birth or early infancy - severe visual impairment (VA < 1/20) from birth
- Nystagmus / roving eye movements - pendular nystagmus or wandering eye movements
- Absent or markedly reduced pupillary light reflexes (or paradoxical - the Flynn phenomenon: pupil constriction in darkness)
- Flat or severely attenuated ERG - this is pathognomonic; a virtually flat full-field ERG in an infant is the defining investigation
Additional clinical signs:
- Oculodigital sign (Franceschetti sign): Child compulsively presses, rubs, or digs fingers/fists into the eyes - orbital fat atrophy follows, causing enophthalmos and subsequent keratoconus or keratoglobus
- Fundus: May appear completely normal in early infancy; later develops mild arteriolar narrowing, salt-and-pepper retinopathy, peripheral pigmentary retinopathy, macular pigmentation or atrophy
- Hypermetropia is the most common refractive error
- Strabismus, cataract
- Systemic associations in some subtypes: intellectual disability, deafness, epilepsy, CNS anomalies, renal anomalies (nephronophthisis - Senior-Løken syndrome), skeletal malformations, obesity (Bardet-Biedl overlap)
- FAF: Hypoautofluorescence in children with RPE65 mutations (lipofuscin cannot accumulate as the visual cycle is blocked)
- OCT patterns (genotype-dependent): may show preserved foveal ONL island (Type 3 in RPE65/CEP290) or diffuse photoreceptor loss
Genetics
LCA is predominantly AR (>95%). Four genes (CRX, IMPDH1, OTX2, TUBB4B) cause AD forms. At least 28 causative genes are known, accounting for ~70% of cases. Key genes by pathway:
| Gene (LCA type) | Pathway | Frequency | Notes |
|---|---|---|---|
| GUCY2D (LCA1) | Phototransduction - retinal guanylate cyclase | ~12% | Severe cone dysfunction predominant |
| RPE65 (LCA2) | Visual/retinoid cycle | ~6-16% | Target of gene therapy (Luxturna) |
| SPATA7 (LCA3) | Photoreceptor morphogenesis | Rare | |
| AIPL1 (LCA4) | Protein folding (PDE6) | ~5% | Severe, rapid degeneration |
| RPGRIP1 (LCA6) | Ciliary transport | ~5% | |
| CRX (LCA7) | Retinal transcription factor | Rare | AD; variable penetrance |
| CRB1 (LCA8) | Cell polarity/tight junctions | ~10% | Also causes RP; nummular deposits characteristic |
| NMNAT1 (LCA9) | NAD biosynthesis | ~3% | Severe macular atrophy |
| CEP290 (LCA10) | Ciliary transport | ~15-20% | Most common LCA gene; IVS26 c.2991+1655A>G mutation in 90%; associated with Joubert/Bardet-Biedl |
| RDH12 (LCA13) | Visual cycle | ~5% | Severe progressive macular atrophy |
| LRAT (LCA14) | Visual cycle | Rare | |
| TULP1 (LCA15) | Photoreceptor structure | ~1% |
(Retina Today 2025; AAO Education; Kanski 10th ed.)
Management
Supportive (all LCA):
- Low vision aids, orientation and mobility training
- Appropriate schooling (special educational needs)
- Rehabilitation and social services support
- UV-protective lenses; photophobia management
- Systemic monitoring for syndromic associations (renal function, CNS, cardiac)
- Genetic testing and counseling for family planning
Gene Therapy - Voretigene Neparvovec (Luxturna):
- Mechanism: Recombinant AAV2 vector carrying a functional copy of the human RPE65 cDNA, delivered by subretinal injection
- Indication: Biallelic RPE65 mutation-associated retinal dystrophy (LCA2 / early-onset RP due to RPE65) with sufficient viable retinal cells
- Approval: FDA approved December 2017 (first in-vivo gene therapy approved in the US); EMA approved 2018. Administered to each eye sequentially (not same session), minimum 6 days apart
- Dose: 1.5 × 10¹¹ vector genomes per eye in 0.3 mL subretinal volume
- Age: Patients ≥1 year (minimum viable retinal cells required)
- Efficacy (Phase 3, Russell et al.): Primary endpoint - multiluminance mobility test (MLMT) showed significant improvement at 1 year. Secondary endpoints: full-field light sensitivity threshold (FST) improved by ~2.5 log units; visual acuity improvement less dramatic. Phase 3 results at 3-4 years (Maguire et al. 2021) confirmed durable functional improvements maintained
- Adverse effects: Postoperative inflammation/vitritis (~50% cases, managed with perioperative corticosteroids), transient IOP elevation, subretinal haematoma, endophthalmitis risk, perifoveal chorioretinal atrophy (Gange et al. 2022)
- Limitation: Does not work in eyes with no viable retinal cells; cost is ~$425,000 USD per eye (PMID: 41140124)
Emerging Therapies:
- Sepofarsen (QR-110): Antisense oligonucleotide targeting CEP290 c.2991+1655A>G IVS26 mutation - Phase 3 HYPERION trial ongoing (2025)
- EDIT-101: CRISPR/Cas9 in-vivo gene editing for CEP290 IVS26 - Phase 1/2 BRILLIANCE trial showed efficacy in majority (Pierce et al. NEJM 2024, PMID available)
- AAV-AIPL1 (LCA4): MeiraGTx showing meaningful VA gains
- GUCY2D (LCA1): Phase 1/2 positive; Phase 3 planned by Atsena/Nippon Shinyaku (2024-2025)
3. Role of Genetic Counseling in Inherited Retinal Disorders
Why Genetic Counseling is Essential
IRDs are caused by mutations in >250 genes with autosomal dominant, AR, X-linked, mitochondrial, and digenic inheritance patterns. Without expert interpretation, genetic testing results can be misleading or incompletely understood by patients and families. (Kanski 10th, p. 638; AAO Clinical Statement 2022)
Core Roles
1. Pre-test Counseling:
- Explain what genetic testing can and cannot determine
- Discuss potential psychological impact (diagnosis certainty, prognosis implications, reproductive implications)
- Prepare family for the possibility of inconclusive results (still 30% of LCA, ~50% of RP unresolved genetically)
- Consent process; choice of test type (panel vs. exome vs. genome)
- Consider patient readiness, especially in asymptomatic at-risk family members
2. Diagnosis Clarification:
- IRDs show extensive genetic heterogeneity (>100 genes cause RP) and phenotypic heterogeneity (same gene causes different clinical phenotypes in different families)
- Genetic testing determines the exact causative gene, enabling precise diagnosis and distinguishing phenocopies (e.g., CRB1-associated LCA vs. RPE65-LCA vs. CEP290-LCA have different prognoses)
- Identifies syndromic forms - Usher syndrome (USH2A, MYO7A - RP + hearing loss), Bardet-Biedl syndrome (CEP290 + obesity + polydactyly + renal), Joubert syndrome - requiring multidisciplinary follow-up
3. Recurrence Risk Assessment:
| Inheritance | Recurrence risk to sibs | Risk to offspring |
|---|---|---|
| Autosomal dominant | 50% | 50% |
| Autosomal recessive | 25% per pregnancy | Very low (unless consanguinity) |
| X-linked recessive | 50% of sons affected; 50% of daughters are carriers | |
| Mitochondrial | Maternal transmission; variable expressivity |
4. Treatment Eligibility:
- Currently the only approved gene therapy for IRD (Luxturna) requires confirmed biallelic RPE65 mutations - genetic testing is mandatory for eligibility
- Genetic diagnosis determines eligibility for clinical trials targeting specific mutations
- Counselors guide families toward appropriate trials (e.g., CEP290 IVS26 → sepofarsen/EDIT-101)
5. Carrier Testing and Cascade Testing:
- Testing unaffected family members to identify carriers (particularly for X-linked and AR forms in consanguineous families)
- Prenatal testing (chorionic villus sampling/amniocentesis) and preimplantation genetic diagnosis (PGD) for couples at high risk
6. Post-test Counseling:
- Interpreting results including variants of uncertain significance (VUS)
- Addressing psychosocial impact of a definitive or inconclusive diagnosis
- Explaining genotype-phenotype correlations and prognosis
- Reassessment over time as variant classifications may change (VUS reclassification)
7. Multidisciplinary Coordination:
- For syndromic IRDs (Usher, BBS, Joubert, Senior-Løken), counselors coordinate referrals to audiology, nephrology, neurology, endocrinology, and paediatric genetics
- Genetic counselors with expertise in ophthalmic genetics are recommended for complex cases
4. Fundus Autofluorescence (FAF) in IRDs
Principle
FAF is a non-invasive imaging technique that maps lipofuscin distribution in the RPE. Lipofuscin accumulates as a byproduct of incomplete lysosomal digestion of shed photoreceptor outer segments. The primary fluorophore is A2E (a bisretinoid), which absorbs blue light (peak excitation ~470 nm) and emits yellow-green light (~600 nm). Areas of RPE loss = hypoAF; areas of stressed/overloaded RPE = hyperAF.
FAF Patterns in Specific IRDs
Retinitis Pigmentosa (rod-cone dystrophy):
- Classic finding: Hyperautofluorescent (hyperAF) ring concentric with and just outside the fovea, corresponding to the transition zone between surviving and dying photoreceptors
- The ring represents the leading edge of degeneration where RPE is stressed and lipofuscin is accumulating before cell death
- Inside the ring: preserved photoreceptors and relatively normal AF
- Outside the ring: hypoAF (RPE atrophy, photoreceptor loss)
- Ring constricts over time correlating with visual field constriction - the ring diameter tracks disease progression and is used as a biomarker in clinical trials
- Mid-peripheral mottled hypoAF represents RPE dropout
- Carriers of X-linked RP: characteristic radial hyperAF streaks at the posterior pole
Cone-Rod Dystrophy:
- Central/foveal hypoAF (central RPE atrophy) surrounded by a ring of hyperAF
- Pattern varies by stage: early = subtle foveal hyperAF or non-specific changes; late = central hypoAF atrophy
- FAF is often "the key diagnostic test" in CRD (Kanski 10th, p. 638)
Stargardt Disease (ABCA4):
- Perifoveal hypoAF (RPE atrophy at macula)
- Surrounding hyperAF flecks (lipofuscin-laden RPE cells unable to process A2-E due to ABCA4 dysfunction)
- "Beaten-bronze" or "snail slime" appearance
- Area of hypoAF correlates with visual loss and is used as a biomarker in natural history studies and trials (rate of spread ~0.3-0.5 mm²/year)
- Dark choroid on FFA (blocked choroidal fluorescence by lipofuscin) - opposite of FAF appearance
Leber Congenital Amaurosis:
- RPE65 mutations: HypoAF in children (visual cycle blocked, so A2E/lipofuscin cannot accumulate - RPE is not loaded with lipofuscin) - this is paradoxically reassuring as viable RPE is present
- CRB1 mutations: Circumferential hyperAF in the macular region and alongside retinal arterioles (para-arteriolar hyperAF is characteristic)
- After Luxturna treatment: FAF can monitor restoration of RPE65 function
CRB1-associated retinal dystrophy:
- Circumferential hyperAF in the macular region and alongside retinal arterioles (para-arteriolar pattern) (Kanski 10th, p. 637)
Choroideremia:
- Advancing scalloped border of hypoAF (loss of RPE/choriocapillaris from periphery inwards) with preserved central AF
Best disease:
- FAF mirrors clinical stages: vitelliform stage = hyperAF; pseudo-hypopyon = layered; scrambled-egg/vitelliruptive = patchy hyperAF + hypoAF; atrophic = hypoAF
MIDD (maternally inherited diabetes and deafness):
- Hyperflecks radiating from central hypoAF, resembling Stargardt
5. Bull's Eye Maculopathy - Differential Diagnosis
Definition
Bull's eye maculopathy describes a concentric ring of RPE hypopigmentation/depigmentation surrounding a central area of relatively preserved (or hyperpigmented) foveal RPE - creating a target-like appearance. On FFA it shows a hyperfluorescent ring with a hypofluorescent center (window defect pattern).
Differential Diagnosis (Kanski Table 15.1 + clinical sources)
In Adults:
| Cause | Key Distinguishing Features |
|---|---|
| Chloroquine/Hydroxychloroquine maculopathy | Drug history (dose, duration >5 years or >1000g cumulative); early detection by OCT (parafoveal thinning), 10-2 visual field, mfERG; bilateral; may progress after drug cessation |
| Cone / Cone-Rod Dystrophy | Photophobia, colour vision loss, reduced VA; abnormal photopic ERG; FAF with annular ring; young adults; genetic testing |
| Advanced Stargardt disease | ABCA4 mutations; pisciform flecks; dark choroid on FFA; onset in childhood; central hypoAF on FAF |
| Benign concentric annular macular dystrophy | Stationary or slowly progressive; AD inheritance; ERG normal |
| Fenestrated sheen macular dystrophy | Sheen visible at macula; AD; stationary |
| Clofazimine retinopathy | Leprosy treatment history; drug-related |
In Children:
| Cause | Key Distinguishing Features |
|---|---|
| Bardet-Biedl syndrome | Obesity, polydactyly, hypogonadism, renal anomalies, intellectual disability; AR; CEP290/BBS genes |
| Leber congenital amaurosis | Congenital blindness, flat ERG, oculodigital sign, nystagmus |
| Hallervorden-Spatz syndrome (PKAN) | Neurodegeneration with brain iron accumulation; PANK2 mutation; eye of the tiger sign on MRI; dystonia |
| Lipofuscinosis (Batten disease / NCL) | Progressive neurodegeneration; seizures; ERG abnormal; storage vacuoles on EM of blood/conjunctiva |
| Autosomal dominant cerebellar ataxia | Cerebellar signs; usually adult-onset |
Additional Causes Not in Kanski Table (complete differential):
- Deferoxamine retinopathy (iron chelation therapy)
- Dideoxyinosine (ddI) retinopathy - antiretroviral
- Age-related pattern (concentric AMD) - older patients
- Fucosidosis, GM1/GM2 gangliosidosis - lysosomal storage disorders in children
Key Differentiating Investigations:
- ERG - most important: photopic ERG abolishes the possibility of normal cones; scotopic for rod-cone vs CRD pattern
- Genetic testing - panel for ABCA4, CRD genes, BBS genes
- OCT - parafoveal outer retinal layer loss (CRD, CQ toxicity); ellipsoid zone disruption
- Drug/medication history - chloroquine, hydroxychloroquine, clofazimine, deferoxamine
- Systemic examination - for syndromic causes (BBS, Hallervorden-Spatz)
6. Autofluorescence (FAF) vs. Fluorescein Angiography (FFA) in RP
Key Comparison
| Feature | FAF | FFA (Fluorescein Angiography) |
|---|---|---|
| Mechanism | Intrinsic lipofuscin fluorescence in RPE | Injected sodium fluorescein dye; images retinal and choroidal circulation |
| Invasiveness | Non-invasive; no injection needed | Invasive; IV fluorescein injection; anaphylaxis risk (~1:200,000); nausea, vomiting common |
| Primary information | RPE metabolic status; lipofuscin distribution | Vascular integrity, perfusion, RPE barrier function (window/blocking defects, leakage) |
| Role in RP | Primary imaging tool for monitoring progression | Limited role; mainly for complications |
| Signal strength | ~100x weaker than FFA | Strong signal; high contrast |
| RP findings on FAF | HyperAF ring (transition zone), mottled peripheral hypoAF, macular changes | Window defects (hyperfluorescence) at atrophic areas; CMO (cystoid macular oedema) shown by FFA |
| RP findings on FFA | - | Arteriolar attenuation; RPE atrophy shows window defects; CMO = petaloid hyperfluorescence at macula; rare choroidal neovascularisation (CNV) |
| Disease progression monitoring | Excellent - ring diameter shrinkage correlates with VF loss; FAF area is a validated biomarker | Poor for monitoring; FFA not recommended for longitudinal follow-up in IRDs |
| Early disease detection | FAF can show abnormalities before visible fundus changes | Less sensitive for subclinical RPE dysfunction |
| Complications assessed | Limited - cannot directly assess CMO or CNV | CMO (a common treatable complication of RP, ~20% prevalence) and CNV reliably detected |
| X-linked RP carriers | Characteristic radial hyperAF streaks | Non-diagnostic |
| Genotype correlation | FAF patterns (ring vs. diffuse) correlate with genotype | Less genotype-specific |
| Practical use in clinic | Routine monitoring tool; serial FAF recommended | Use when complication suspected (CMO, CNV) or initial diagnosis workup |
When to Use FFA in RP
FFA is not needed for diagnosis of RP, and is "never needed these days" for cone-rod dystrophy diagnosis per Kanski 10th ed. (p. 638). However, FFA is indicated in RP when:
- Suspicion of cystoid macular oedema (CMO) - confirmed by FFA and OCT; treatment response monitored
- Suspected choroidal neovascularisation (rare but treatable complication)
- Atypical presentations requiring differential diagnosis
- Initial workup in centres without OCT/FAF
(Springer Nature - Ultra-widefield imaging review; Retinal Physician 2021; PMC12293359 - FAF in IRD review 2025)
FAF Findings in RP - Summary
The hyperAF ring in RP has important clinical implications:
- Its area and its rate of contraction predict rate of visual field loss
- Studies correlate ring border with the parafoveal border of the visual field on microperimetry
- Ultra-widefield FAF can detect peripheral hypoAF years before visible fundoscopic changes
- Near-infrared FAF (NIR-FAF) at 787 nm detects melanin/melanolipofuscin in addition to lipofuscin - shows different patterns and can be more sensitive for RPE degeneration at the periphery
Sources: Kanski's Clinical Ophthalmology 10th Edition (Chapter 15, pp. 631-660) | Retina Today July/Aug 2025 | AAO IRD Clinical Assessment Guidelines 2022 | PMC12293359 (FAF in IRDs, 2025) | PMC on Cone-rod Dystrophies | Retina 5th Edition (Miyake & Shinoda) | PMID 34532415 (Gene therapy for IRDs, Ann Transl Med 2021) | PMID 41140124 (Luxturna safety/pharmacovigilance 2025)
This is a shared conversation. Sign in to Orris to start your own chat.